Pharmosa Biopharm Past Earnings Performance
Past criteria checks 2/6
Pharmosa Biopharm has been growing earnings at an average annual rate of 22.7%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 157.4% per year. Pharmosa Biopharm's return on equity is 0.7%, and it has net margins of 2.7%.
Key information
22.7%
Earnings growth rate
41.6%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 157.4% |
| Return on equity | 0.7% |
| Net Margin | 2.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Pharmosa Biopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 315 | 8 | 40 | 277 |
| 30 Sep 23 | 315 | 55 | 36 | 239 |
| 30 Jun 23 | 0 | -238 | 32 | 214 |
| 31 Mar 23 | 0 | -252 | 31 | 228 |
| 31 Dec 22 | 0 | -267 | 29 | 242 |
| 30 Sep 22 | 0 | -297 | 27 | 275 |
| 30 Jun 22 | 0 | -310 | 25 | 288 |
| 31 Mar 22 | 0 | -283 | 21 | 265 |
| 31 Dec 21 | 0 | -256 | 18 | 241 |
| 30 Sep 21 | 0 | -235 | 16 | 222 |
| 30 Jun 21 | 0 | -213 | 14 | 203 |
| 31 Mar 21 | 0 | -197 | 13 | 189 |
Quality Earnings: 6875 has a high level of non-cash earnings.
Growing Profit Margin: 6875 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6875 has become profitable over the past 5 years.
Accelerating Growth: 6875 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 6875 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 6875's Return on Equity (0.7%) is considered low.